MICROBIOLOGICAL PROPERTIES OF AIRBORNE INFECTIONS AND MODERN PROPHYLAXIS STRATEGIES AGAINST THEM
Keywords:
airborne infections, influenza virus, microbiology, antigenic variability, prevention, immunization.Abstract
The microbiological characteristics of airborne infectious diseases, their transmission mechanisms and epidemiological significance are analyzed in this literature review. In particular, the structure, antigenic properties, variability, pathogenesis and resistance to environmental factors of the Influenza virus are scientifically covered.
The article also considers modern prevention strategies, including vaccines, sanitary and hygienic measures, disinfection measures and comprehensive approaches aimed at strengthening public health. The results of the study show that early diagnosis, regular epidemiological surveillance and effective immunoprophylaxis are important in preventing airborne infections.
References
1. 2021 Aug 27;373(6558):eabd9149. Airborne transmission of respiratory virus.
2. 2023 Jun 20;14Pathogenicity and virulence of influenza.Yuying liang
3. Smyk JM, Szydłowska N, Szulc W, et al. Evolution of influenza viruses—drug resistance, treatment options, and prospects. IJMS. 2022;23(20):12244. doi: 10.3390/ijms232012244.
4. Liu R, Sheng Z, Huang C, et al. Influenza D virus. Curr Opin Virol. 2020;44:154–161. doi: 10.1016/j.coviro.2020.08.004
5. Iuliano A.D., Roguski K.M., Chang H.H., et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. The Lancet, 2018.
6. Krammer F., Smith G.J.D., Fouchier R.A.M., et al. Influenza. Nature Reviews Disease Primers, 2018.
7. Murray P.R., Rosenthal K.S., Pfaller M.A. Medical Microbiology. 9th ed. Elsevier, 2020.
8. World Health Organization. Influenza (Seasonal) Fact Sheet. WHO, 2023.
9. Krammer F. et al. Influenza. Nature Reviews Disease Primers, 2018.
10. Jawetz, Melnick & Adelberg’s. Medical Microbiology. 28th ed. McGraw-Hill, 2019.
11. Taubenberger J.K., Kash J.C. Influenza virus evolution, host adaptation, and pandemic formation. Cell Host & Microbe, 2010.
12. Abbas A.K., Lichtman A.H., Pillai S. Cellular and Molecular Immunology. 10th ed. Elsevier, 2021.
13. Nicholls J.M. et al. Tropism of influenza virus for respiratory epithelium. Journal of Pathology, 2007.
14. Webster R.G. et al. Evolution and ecology of influenza A viruses. Microbiological Reviews, 1992.
15. Taubenberger J.K., Morens D.M. 1918 Influenza: the mother of all pandemics. Emerging Infectious Diseases, 2006.
16. Centers for Disease Control and Prevention (CDC). How Influenza Vaccines Are Made. CDC, 2022.
17. Morawska L, Cao J. Airborne transmission of SARS-CoV-2: The world should face the reality. Environment International. 2020;139:105730. doi:10.1016/j.envint.2020.105730
18. Iuliano AD, Roguski KM, Chang HH, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. The Lancet. 2018;391(10127):1285–1300. doi:10.1016/S0140-6736(17)33293-2
19. Reed C, Chaves SS, Perez A, et al. Complications among adults hospitalized with influenza: A comparison of seasonal influenza and the 2009 H1N1 pandemic. Clinical Infectious Diseases. 2014;59(2):166–174. doi:10.1093/cid/ciu285
20. Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. New England Journal of Medicine. 1999;341(18):1336–1343. doi:10.1056/NEJM199910283411802
21. Murray PR, Rosenthal KS, Pfaller MA. Medical Microbiology. 9th ed. Philadelphia: Elsevier; 2020.
22. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. New England Journal of Medicine. 2020;382:727–733. doi:10.1056/NEJMoa2001017
23. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2. Cell. 2020;181(2):271–280.e8. doi:10.1016/j.cell.2020.02.052
24. RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. New England Journal of Medicine. 2021;384:693–704. doi:10.1056/NEJMoa2021436
25. [10] Moss WJ. Measles. The Lancet. 2017;390(10111):2490–2502. doi:10.1016/S0140-6736(17)31463-0
26. Shi T, McAllister DA, O’Brien KL, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children. The Lancet Respiratory Medicine. 2017;5(2):149–159. doi:10.1016/S2213-2600(16)30403-1
27. Lynch JP, Fishbein M, Echavarria M. Adenovirus infections in transplant recipients. Clinical Microbiology Reviews. 2011;24(3):430–459. doi:10.1128/CMR.00052-10
28. Belongia EA, Simpson MD, King JP, et al. Variable influenza vaccine effectiveness. Clin Infect Dis. 2016.
29. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020.
30. Moss WJ. Measles. Lancet. 2017.
31. Thompson MG, Shay DK, Zhou H, et al. Influenza vaccination effectiveness. N Engl J Med. 2010.
